Journal of Oncology / 2010 / Article / Tab 1

Review Article

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Table 1

Completed clinical trials evaluating potential drug targets of BRCA1.

Drug classCompoundPhaseStudy population

PARP inhibitorsKU-0059436 (AZD2281)Phase IBRCA1/2 germline mutation in advanced breast and EOC [23]

HDAC inhibitorsSAHA (vorinostat)Phase IIRecurrent EOC [24]

CHK inhibitorsUCN-01 (staurosporine derivative) in combination with topotecanPhase IAdvanced solid tumors, including EOC [25]
UCN-01 in combination with topotecanPhase IIRecurrent EOC [26]

Proteasome inhibitorsPS-341 (bortezomib) in combination with carboplatinPhase IRecurrent EOC [27]
PS-341 in combination with carboplatinPhase IPlatinum/taxane resistant EOC [28]
PS-341Phase IIRecurrent, platinum-sensitive EOC [29]
PS-341 in combination with paclitaxelPhase IAdvanced solid tumours, including EOC [30]